1. Scrip
  2. >>Business
  3. >>Manufacturing

Lachman CEO On Compliance And Living The Code Of Conduct

 
• By Anju Ghangurde

Frances Zipp, president and CEO of Lachman Consultant Services, Inc, in an interview with Scrip, emphasizes the importance of the ‘cultural element’ and top management engagement in addressing compliance issues, including those pertaining to data integrity, at Indian firms.

Zipp_Frances
Lachman President And CEO Frances Zipp

Data integrity and manufacturing compliance issues have stung Indian drug firms over the recent past, eroding both growth and reputation. And with the US Food and Drug Administration expected to increase its foreign pre-approval ANDA and GMP inspections in FY2019, the Indian pharma industry will likely need to cover significant ground to meet evolving compliance requirements and achieve sustainable excellence in quality and compliance.

Lachman Consultant Services, Inc, which is a leading provider of expert compliance, regulatory affairs and technical services to the life...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing

More from Business

2030’s Top Therapies: Incretin Agonists Loom Large

 
• By Edwin Elmhirst

Scrip looks at the therapies projected to lead global sales by 2030. These frontrunners not only reflect advances in innovation but also shifting priorities in chronic disease management.

Lupin Confident Of US Growth On Tariff Mitigation, Rides High On Tolvaptan

 
• By Vibha Ravi

Lupin is hoping moves like intellectual property transfer for some products to the US will help mitigate the tariff impact even as it counts on growth from planned launches of GLP-1s and biosimilars while riding high on tolvaptan launched in Q1.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Trump ups pressure on MFN pricing; Pfizer says pharma working with Trump on direct sales; Sanofi says direct sales worth considering: Aurigene Oncology CEO on biotech valuations and more; and Novartis progresses pipeline-in-a-product assets.